N/A
N=12
Improving Hallucinations by Targeting the rSTS With tES
Hallucinations, Auditory · Psychosis
Bottom Line
View on ClinicalTrials.gov: NCT05165654 ↗Enrolled (actual)
12
Serious AEs
0.0%
Results posted
Sep 2025
Primary outcome: Primary: Positive and Negative Syndrome Scale (PANSS) — 60.5; 60; 56; 63 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Transcranial Electrical Stimulation (Device)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Beth Israel Deaconess Medical Center
- Primary completion
- Jun 2025
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Positive and Negative Syndrome Scale (PANSS) |
60.5; 60; 58.5; 70.5 | — |
| PRIMARY Positive and Negative Syndrome Scale (PANSS) |
60.5; 60; 58.5; 70.5 | — |
| PRIMARY University of Miami Parkinson's Disease Hallucinations Questionnaire (UM-PDHQ) |
1.85; 1.9; 1.4; 2.35 | — |
| PRIMARY University of Miami Parkinson's Disease Hallucinations Questionnaire (UM-PDHQ) |
1.85; 1.9; 1.4; 2.35 | — |
| PRIMARY 7-item Auditory Hallucinations Rating Scale (AHRS) |
0; 8; 0; 6 | — |
| PRIMARY 7-item Auditory Hallucinations Rating Scale (AHRS) |
0; 8; 0; 6 | — |
| SECONDARY Auditory Steady State Evoked Potential |
0.369044853; 0.434681797; 0.307252913; 0.221649958 | — |
| SECONDARY Auditory Steady State Evoked Potential |
0.369044853; 0.434681797; 0.307252913; 0.221649958 | — |
| SECONDARY Steady State Visual Evoked Potential |
-0.62131125; -0.046333327; 0.276320034; -0.342125912 | — |
| SECONDARY Steady State Visual Evoked Potential |
-0.62131125; -0.046333327; 0.276320034; -0.342125912 | — |
| SECONDARY Cross Modal Steady State Evoked Potential |
-0.129873057; -0.225582699; -0.372064254; -0.370288832 | — |
| SECONDARY Cross Modal Steady State Evoked Potential |
-0.129873057; -0.225582699; -0.372064254; -0.370288832 | — |
| SECONDARY Resting State EEG |
-6.067479336; -9.836502863; -5.891239776; -8.925939219; -7.920960953; -11.66579035 | — |
| SECONDARY Resting State EEG |
-6.067479336; -9.836502863; -5.891239776; -8.925939219; -7.920960953; -11.66579035 | — |
| SECONDARY Biological Motion |
87.5; 85; 95; 85 | — |
| SECONDARY Biological Motion |
87.5; 85; 95; 85 | — |
| SECONDARY Neurological Evaluation Scale; Sensory Integration |
— | — |
| SECONDARY Neurological Evaluation Scale; Sensory Integration |
— | — |
| SECONDARY Global Assessment of Function (GAF) |
60.5; 57.5; 61.5; 54 | — |
| SECONDARY Global Assessment of Function (GAF) |
60.5; 57.5; 61.5; 54 | — |
| SECONDARY Montgomery-Asberg Depression Rating Scale (MADRS) |
7; 7.5; 5.5; 13 | — |
| SECONDARY Montgomery-Asberg Depression Rating Scale (MADRS) |
7; 7.5; 5.5; 13 | — |
| SECONDARY Young Mania Rating Scale (YMRS) |
2.25; 7; 2; 8.75 | — |
| SECONDARY Young Mania Rating Scale (YMRS) |
2.25; 7; 2; 8.75 | — |
| SECONDARY Brief Assessment of Cognition (BACS) |
0.58; -0.8; -0.07; -1.425 | — |
| SECONDARY Brief Assessment of Cognition (BACS) |
0.58; -0.8; -0.07; -1.425 | — |
| SECONDARY Symptom Checklist-90 |
56.5; 81.5; 42; 95.5 | — |
| SECONDARY Symptom Checklist-90 |
56.5; 81.5; 42; 95.5 | — |
Summary
Hallucinations are a core diagnostic feature of psychotic disorders. They involve different sensory modalities, including auditory, visual, olfactory, tactile, and gustatory hallucinations, among others. Hallucinations occur in multiple different neurological and psychiatric illnesses and can be refractory to existing treatments. Auditory hallucinations and visual hallucinations are found across diagnostic categories of psychotic disorders (schizophrenia, schizoaffective, bipolar disorder). Despite visual hallucinations being approximately half as frequent as auditory hallucinations, they almost always co-occur with auditory hallucinations, and are linked to a more severe psychopathological profile. Auditory and visual hallucinations at baseline also predict higher disability, risk of relapse and duration of psychosis after 1 and 2 years, especially when they occur in combination. Using a newly validated technique termed lesion network mapping, researchers demonstrated that focal brain lesions connected to the right superior temporal sulcus (rSTS) plays a causal role in the development of hallucinations. The rSTS receives convergent somatosensory, auditory, and visual inputs, and is regarded as a site for multimodal sensory integration. Here the investigators aim to answer the question whether noninvasive brain stimulation when optimally targeted to the rSTS can improve brain activity, sensory integration, and hallucinations.
Eligibility Criteria
Inclusion Criteria
- Aged 18-50 years of age
- Proficient in English
- Able to give informed consent
- Actively experiencing hallucinations (tactile, auditory, visual, etc.)
- Has not recently participated in tES/TMS treatments
Exclusion Criteria
- Substance abuse or dependence (w/in past 6 months)
- Those who are pregnant/breastfeeding
- History of head injury with > 15 minutes of loss of consciousness/mal sequelae
- DSM-V intellectual disability
- Having a non-removable ferromagnetic metal within the body (particularly in the head)
- History of seizures
Data sourced from ClinicalTrials.gov (NCT05165654). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.